Alivus Life Sciences Ltd

Alivus Life Sciences Reports Record Q3FY26 Results & Expansion Plans 🚀

- Record Q3FY26 revenue: ₹6,729 Mn (14.4% QoQ, 4.8% YoY growth)

- Q3FY26 EBITDA: ₹2,452 Mn (26.5% QoQ, 22.1% YoY growth), with record 36.4% margin

- Q3FY26 PAT: ₹1,503 Mn (15.5% QoQ, 9.7% YoY growth), 22.3% margin

- 9MFY26 revenue: ₹18,627 Mn (7.2% YoY growth)

- 9MFY26 EBITDA: ₹6,204 Mn (22.0% YoY growth)

- 9MFY26 PAT: ₹4,019 Mn (16.9% YoY growth)

- Strong free cash flow: ₹2,207 Mn in 9MFY26; cash reserves at ₹7,330 Mn (Dec 31, 2025)

- Non-GPL business grew 16% YoY in 9MFY26, in-line with guidance

- Total DMF/CEP filings: 595 (as of Dec 31, 2025)

- HP API portfolio: 27 products (9 validated, 7 in advanced dev, 11 in lab dev)

- Expansion: 465 KL capacity under construction in Solapur; 10,000 sqm R&D land acquired in Taloja

- Net debt-free with 176 molecules & 4 globally inspected facilities